Background: Signal transducer and activator of transcription 6 (STAT6) is a key transcription factor involved in both interleukin-4 (IL-4) and IL-13-mediated biological responses, such as allergies. Recently, we reported that the polymorphism of the STAT6 gene exon 1 was associated with allergic diseases, while another group studied the G2964A variant of the STAT6 gene’s association with atopic asthma. We undertook an association study between these variants of the STAT6 gene and allergic diseases, including atopic dermatitis, bronchial asthma, and food-related anaphylaxis in a Japanese population. Methods: STAT6 gene polymorphisms were genotyped by polymerase chain reaction (PCR) fragment length polymorphism analysis, and PCR-SSCP analysis in 106 allergic and 66 control subjects. Results: The 2964A variant was in significant linkage disequilibrium with the dinucleotide repeat polymorphism, the 13-GT repeat allele of STAT6 exon 1 (p < 0.0000000003). There was no association between the STAT6 2964A variant and allergic subjects in a Japanese population (p = 0.2724). The genotype of 13/15-GT repeat allele heterozygosity was significantly associated with allergic subjects (p = 0.0006), as previously reported. In one major genotype of the STAT6 exon 1 (15 GT repeat homozygosity), wild-type 2964G allele homozygosity was significantly associated with allergic subjects (p = 0.0382). Conclusions: Our findings indicate that in combination the dinucleotide repeat polymorphism of the STAT6 exon 1 gene and the 2964A variant may be useful markers for predicting allergic diseases in a Japanese population.

1.
Gauchat JF, Lebman DA, Coffman RL, Gascan H, de Vries J: Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med 1990;172:463–473.
2.
Izuhara K, Shirakawa T: Signal transduction via the interleukin-4 receptor and its correlation with atopy. Int J Mol Med 1999;3:3–10.
3.
Hou J, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL: An interleukin-4-induced transcription factor: IL-4 Stat. Science 1994;265:1701–1706.
4.
Ihle JN: Cytokine receptor signalling: Nature 1995;377:591–594.
5.
Schindler C, Darnell JE Jr: Transcription responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 1995;64:621–651.
6.
Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S: Essential role of Stat6 in IL-4 signalling. Nature 1996;380:627–630.
7.
Malabarba MG, Rui H, Deutsch HH, Chung J, Kalthoff FS, Farrar WL, Kirken RA: Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor γ and interleukin-4 receptor α. Biochem J 1996;319:865–872.
8.
Takeda K, Kishimoto T, Akira S: STAT6: Its role in interleukin 4-mediated biological functions. J Mol Med 1997;75:317–326.
9.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD: Interleukin-13: Central mediator of allergic asthma. Science 1998;282:2258–2261.
10.
Akimoto T, Numata F, Tamura M, Takata Y, Higashida N, Takashi T, Takeda K, Akira S: Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 1998;187:1537–3542.
11.
Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA: The association of atopy with a gain-of-function mutation in the α-subunit of the interleukin-4 receptor: N Engl J Med 1997;337:1720–1725.
12.
Kawashima T, Noguchi E, Arinami T, Yamakawa KK, Nakagawa H, Otsuka F, Hamaguchi H: Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 1998;35:502–504.
13.
Kruse S, Japha T, Tedner M, Sparholt SH, Forster J, Kuehr J, Deichmann KA: The polymorphisms S503P and Q576R in the interleukin-4 receptor α gene are associated with atopy and influence the signal transduction. Immunology 1999;96:365–371.
14.
Mitsuyasu H, Yanagihara Y, Mao XQ, Gao PS, Arinobu Y, Ihara K, Takabayashi A, Hara T, Enomoto T, Sasaki S, Kawai M, Hamasaki N, Shirakawa T, Hopkin JM, Izuhara K: Dominant effect of Ile50Val variant of the human IL-4 receptor α-chain in IgE synthesis. J Immunol 1999;162:1227–1231.
15.
Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kobayashi K, Imoto N, Nakahara S, Matsui A, Hamaguchi H: Lack of association of atopy/asthma and the interleukin-4 receptor α gene in Japanese. Clin Exp Allergy 1999;29:228–233.
16.
Heinzmann A, Mao XQ, Akaiwa M, Kreomer RT, Gao PS, Ohshima K, Umeshita R, Abe Y, Braun S, Yamashita T, Roberts MH, Sugimoto R, Arima K, Arinobu Y, Yu B, Kruse S, Enomoto T, Dake Y, Kawai M, Shimazu S, Sasaki S, Adra CN, Kitaichi M, Inoue H, Yamauchi K, Tomichi N, Kurimoto F, Hamasaki N, Hopkin JM, Izuhara K, Shirakawa T, Deichmann KA: Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 2000;9:549–559.
17.
Ober C, Leavitt SA, Tsalenko A, Howard TD, Hoki DM, Daniel R, Newman DL, Wu X, Parry R, Lester LA, Solway J, Blumenthal M, King RA, Xu J, Meyers DA, Bleecker ER, Cox NJ: Variation in the interleukin 4-receptor α gene confers susceptibility to asthma and atopy in ethnically diverse populations. Am J Hum Genet 2000;66:517–526.
18.
Gao PS, Mao XQ, Roberts MH, Arinobu Y, Akaiwa M, Enomoto T, Dake Y, Kawai M, Sasaki S, Hamasaki N, Izuhara K, Shriakawa T, Hopkin JM: Variants of STAT6 (signal transducer and activator of transcription 6) in atopic asthma. J Med Genet 2000;37:380–3282.
19.
Tamura K, Arakawa H, Suzuki M, Kobayashi Y, Mochizuki H, Kato M, Tokuyama K, Morikawa A: Novel dinucleotide repeat polymorphism in the first exon of the STAT-6 gene is associated with allergic diseases. Clin Exp Allergy 2001;31:1509–1514.
20.
Hanifin J, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;suppl 92:44–47.
21.
National Heart Lung Blood Institute, National Institutes of Health. Guidelines for the diagnosis and management of asthma. Washington, Government Printing Office, 1995.
22.
Patel BK, Keck CL, O’Leary RS, Popescu NC, LaRochelle WJ: Localization of the human Stat6 gene to chromosome 12q13.3-q14.1, a region implicated in multiple solid tumors. Genomics 1998;52:192–200.
23.
Postma DS, Koppelman GH, Meyers DA: The genetics of atopy and airway hyperresponsiveness. Am J Respir Crit Care Med 2000;162:S118–S123.
24.
Barnes KC, Freidhoff LR, Nickel R, Chiu YF, Juo SH, Hizawa N, Naidu RP, Ehrlich E, Duffy DL, Schou C, Levett PN, Marsh DG, Beaty TH: Dense mapping of chromosome 12q13.13-q23.3 and linkage to asthma and atopy. J Allergy Clin Immunol 1999;104:485–491.
25.
Collaborative Study on the Genetics of Asthma (CSGA). A genome-wide search for asthma susceptibility loci in ethnically diverse populations. Nature Genet 1997;145:389–392.
26.
Heinzmann A, Grotherr P, Jerkic SP, Lichtenberg A, Braun S, Kruse J, Forster J, Kuehr J, Deichmann KA: Studies on linkage and association of atopy with the chromosomal region 12q13-24. Clin Exp Allergy 2000;30:1554–1561.
27.
Duetsch G, Illig T, Loesgen S, Rohde K, Klopp N, Herbon N, Gohlke H, Altmueller J, Wjst M: STAT6 as an asthma candidate gene: Polymorphism-screening, association and haplotype analysis in a Caucasian sib-pair study: Hum Mol Genet 2002;11:613–621.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.